Vimta Labs posts Q1 FY25consolidated PAT at Rs. 12.28 Cr

Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024

Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan

Lupin divests US commercial women's health specialty business to Evofem

Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones

Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India

Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders

Merck completes acquisition of EyeBio

Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret

Suven Pharmaceuticals gets Form 483 from with two observations from USFDA for Casper Pharma

The company will address these observations within the stipulated timeline

Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial

Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension

Veerhealth Care secures export order from US Institutional Supplier

The company is planning to expand its plant capacity in in Vapi

Piramal Pharma’s Ahmedabad facility completes USFDA PAI

7th India-Japan medical product regulatory symposium held at New Delhi

Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations